Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Am J Cardiol ; 210: 130-132, 2024 Jan 01.
Article in English | MEDLINE | ID: mdl-37884265
2.
Int J Angiol ; 30(1): 53-66, 2021 Mar.
Article in English | MEDLINE | ID: mdl-34025096

ABSTRACT

Despite the widespread adoption of primary percutaneous intervention and modern antithrombotic therapy, ST-segment elevation myocardial infarction (STEMI) remains the leading cause of death in the United States and remains one of the most important causes of morbidity and mortality worldwide. Certain high-risk patients present a challenge for diagnosis and treatment. The widespread adoption of primary percutaneous intervention in addition to modern antithrombotic therapy has resulted in substantial improvement in the short- and long-term prognosis following STEMI. In this review, we aim to provide a brief analysis of the state-of-the-art treatment for patients presenting with STEMI, focusing on cardiogenic shock, current treatment and controversies, cardiac arrest, and diagnosis and treatment of mechanical complications, as well as multivessel and left main-related STEMI.

3.
Heart Views ; 19(2): 63-66, 2018.
Article in English | MEDLINE | ID: mdl-30505397

ABSTRACT

Iatrogenic acute dissection of ascending aorta following coronary angiography and percutaneous intervention is a rare complication. Most reports involve localized aortic dissections as a complication of cannulation of a coronary artery with propagation into the ascending aorta. It is usually treated by sealing the intima with a stent in the ostium of the coronary artery or conservative management, while extensive dissections may require a surgical intervention. We describe a case of the subclavian dissection extending into the ascending aorta that occurred during diagnostic catheterization using the radial approach. The patient was successfully treated utilizing conservative management.

4.
Curr Cardiol Rep ; 20(11): 124, 2018 10 01.
Article in English | MEDLINE | ID: mdl-30276495

ABSTRACT

PURPOSE OF REVIEW: The purpose of this review is to examine current evidence on the benefit of chronic total occlusion (CTO) revascularization in patients with ischemic cardiomyopathy and propose a systematic approach on how and when to accomplish revascularization in these patients. RECENT FINDINGS: Coronary revascularization in patients with reduced ejection fraction (EF) is advocated for to improve left ventricular function and consequently clinical outcomes. Approximately 16-31% of angiograms in patients with advanced CAD are noted to have a concomitant coronary CTO. Its presence is a main predictor of worse outcomes. Over the past 15 years, advancements in interventional technologies and techniques have made it possible to treat CTO lesions percutaneously with success rates exceeding 90%. Different revascularization techniques have been organized into widely used algorithms for systematic CTO lesion crossing and treatment. Patients with reduced EF can be revascularized percutaneously with goal of complete functional revascularization. However, randomized prospective data is needed to justify the increased patient risks and healthcare costs associated with these procedures.


Subject(s)
Cardiomyopathies/therapy , Coronary Occlusion/therapy , Humans , Percutaneous Coronary Intervention , Stroke Volume , Treatment Outcome , Ventricular Dysfunction, Left
5.
J Invasive Cardiol ; 18(3): E102-4, 2006 Mar.
Article in English | MEDLINE | ID: mdl-16495602

ABSTRACT

The compression of the left main coronary artery (LMCA) secondary to pulmonary artery trunk dilatation is a relatively new entity that has been associated with severe pulmonary hypertension. It is associated with acyanogen congenital cardiopathies or idiopathic pulmonary arterial hypertension. The natural history is unknown and its treatment has been based more on the severity of the angiographic compression than on the objective demonstration of myocardial ischemia. We report a case of a woman with severe pulmonary arterial hypertension due to an atrial septal defect with extrinsic compression of the LMCA and a physiopathologic approach to guide its treatment.


Subject(s)
Blood Pressure Determination/instrumentation , Coronary Stenosis/diagnostic imaging , Coronary Stenosis/etiology , Hypertension, Pulmonary/complications , Ultrasonography, Interventional , Constriction, Pathologic , Coronary Angiography , Coronary Stenosis/diagnosis , Coronary Stenosis/physiopathology , Coronary Vessels/physiopathology , Female , Humans , Magnetic Resonance Imaging , Middle Aged , Syndrome
6.
J Am Coll Cardiol ; 46(8): 1466-72, 2005 Oct 18.
Article in English | MEDLINE | ID: mdl-16226169

ABSTRACT

OBJECTIVES: The purpose of this research was to define the predictors of the "slow-reflow" phenomenon during carotid artery intervention with filter-type embolic protection devices (EPDs) and to determine its prognostic significance. BACKGROUND: During carotid artery intervention using filter-type EPDs, we have observed cases in which there is angiographic evidence of a significant reduction in antegrade flow in the internal carotid artery proximal to the filter device, termed "slow-flow." The predictors of this phenomenon and its prognostic significance are unknown. METHODS: Using a single-center prospective carotid intervention registry, patients with slow-flow were compared to patients with normal flow during carotid intervention with respect to clinical, procedural, and lesion characteristics, and the 30-day incidence of death and stroke. RESULTS: A total of 414 patients underwent 453 carotid artery interventions using EPDs. Slow-flow occurred in 42 patients (10.1%) undergoing 42 carotid interventions (9.3%), and most commonly occurred after post-stent balloon dilatation (71.4%). Multivariate logistic regression analysis identified the following predictors of slow-flow: recent history (<6 months) of stroke or transient ischemic attack (odds ratio [OR] 2.8, 95% confidence interval [CI] 1.4 to 5.6, p = 0.004), increased stent diameter (OR 1.4, 95% CI 1.02 to 1.94, p = 0.044), and increased patient age (OR 1.05, 95% CI 1.01 to 1.09, p = 0.025). Among patients with slow-flow, the 30-day incidence of stroke or death was 9.5% compared to 2.9% in patients with normal flow (chi-square = 4.73, p = 0.03). This difference was driven by the disparity in the 30-day incidence of stroke (9.5% vs. 1.7%). CONCLUSIONS: Slow-flow during carotid intervention with EPDs is a frequent event that is associated with an excess risk of periprocedural stroke. The association of the phenomenon with clinically symptomatic carotid lesions and use of larger stent diameters suggests that embolization of vulnerable plaque elements may play a pathogenic role.


Subject(s)
Carotid Stenosis/physiopathology , Carotid Stenosis/surgery , Embolism/prevention & control , Stents , Aged , Blood Flow Velocity , Female , Humans , Male , Prognosis , Prospective Studies
8.
Am Heart J ; 147(1): 31-4, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14691415

ABSTRACT

BACKGROUND: The use of arteriotomy closure devices (CDs) to achieve hemostasis after femoral artery access in percutaneous coronary intervention is steadily increasing. However, the safety information with these devices in the era of triple antiplatelet therapy is limited. METHODS: We reviewed prospectively collected data from the Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET), where all patients received aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitor therapy. At the treating physician's discretion, manual compression (MC) or a vascular hemostasis device was selected following femoral angiography. Patients receiving MC were to have sheaths removed 2 to 6 hours postprocedure when the activated clotting time was < or = 175 seconds. RESULTS: Of 4809 patients, 4736 had femoral access, and 985 of these had a CD (Perclose 47%, Angio-Seal 43%, VasoSeal 5%, and other 5%). The MC and CD groups were similar regarding most demographic characteristics, including age, systolic blood pressure, and weight, but those with MC were more often female, diabetic, and had history of peripheral vascular disease. Patients with a CD had a lower ischemic event rate suggesting they were a lower risk cohort overall. There were no differences in major bleeding at the access site (0.4% vs 0.5%, P =.588), minor bleeding at the access site (1.9% vs. 3.1%, P =.142) or transfusions (0.8% vs 1.0%, P =.513) between the MC and CD groups, respectively. CONCLUSIONS: In contemporary percutaneous coronary intervention practice, with appropriate patient selection, a CD can be safely utilized despite aggressive polypharmacy for procedural anticoagulation.


Subject(s)
Angioplasty, Balloon, Coronary/adverse effects , Femoral Artery , Hemorrhage/prevention & control , Hemostasis, Surgical/instrumentation , Platelet Aggregation Inhibitors/adverse effects , Ticlopidine/analogs & derivatives , Aspirin/adverse effects , Aspirin/therapeutic use , Clopidogrel , Double-Blind Method , Drug Therapy, Combination , Female , Heparin/adverse effects , Heparin/therapeutic use , Humans , Male , Middle Aged , Patient Selection , Platelet Aggregation Inhibitors/therapeutic use , Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors , Prospective Studies , Suture Techniques , Ticlopidine/therapeutic use
9.
Am Heart J ; 148(6): 1003-6, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15632885

ABSTRACT

BACKGROUND: Use of emboli protection devices (EPD) during saphenous vein graft percutaneous coronary intervention (SVG-PCI) has been proven to reduce major adverse cardiac events (MACE). However, the impact of EPD on the microcirculation using Thrombolysis in Myocardial Infarction myocardial perfusion grade (TMP) has not been fully characterized. We sought to analyze TMP after SVG-PCI with and without EPD and determine its impact on inhospital MACE. METHODS: From August 2001 to December 2002, 305 patients had SVG-PCI suitable for EPD; 210 (69%) had an angiogram appropriate for TMP evaluation. Of those, 46 (22%) had an EPD (GuardWire, Medtronic, Minneapolis, Minn) deployed during the coronary intervention. Both groups were similar with regard to most demographic and clinical features. RESULTS: A TMP score of 2.5 or 3 was obtained in 98% of the EPD group versus 85% of the unprotected SVG-PCI (P = .01). There was a trend towards reduction in MACE when using EPD (15% vs 27%, respectively, P = .07). Peak postprocedural creatine kinase-MB was somewhat lower in the EPD group (6.03 +/- 7.8 ng/mL vs 14.87 +/- 42 ng/mL, P = .17) Patients with a TMP grade of 2.5 or 3 had a statistically significant reduction in MACE (OR 0.36, 95% CI 0.14-0.87, P = .02). CONCLUSIONS: Compared with SVG-PCI without emboli protection, EPD significantly improved TMP and trended towards a reduction in MACE.


Subject(s)
Angioplasty, Balloon, Coronary/instrumentation , Coronary Disease/therapy , Embolism/prevention & control , Graft Occlusion, Vascular/therapy , Aged , Angina, Unstable/therapy , Coronary Artery Bypass , Coronary Circulation , Coronary Disease/physiopathology , Female , Humans , Male , Multivariate Analysis , Myocardial Infarction/prevention & control , Risk Factors , Saphenous Vein/transplantation , Stroke Volume
SELECTION OF CITATIONS
SEARCH DETAIL
...